Hematopoiesis News

Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.

Subscribe|Follow Us On

An Epigenetic Pathway Regulates MHC-II Expression and Function in B Cell Lymphoma Models

January 17, 2025

[Journal of Clinical Investigation] Scientists elucidated how BRCA1 associated protein 1 (BAP1) was involved in transcriptional regulation of MHC-II expression and how BAP1 impacted B cell lymphoma tumor growth via regulating tumor microenvironment and immune cell infiltration.

Generating Allogeneic CAR-NKT Cells for Off-the-Shelf Cancer Immunotherapy with Genetically Engineered HSP Cells and Feeder-Free Differentiation Culture

January 17, 2025

[Nature Protocols] Researchers introduced an ex vivo feeder-free culture method to differentiate gene-engineered hematopoietic stem and progenitor cells into allogeneic invariant natural killer T cells and their CAR-armed derivatives.

Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia

January 16, 2025

[Blood] Researchers performed apolipoprotein E (APOE) genotyping in two contemporary cohorts of 348 and 447 patients with AML who had received allogeneic HSCT and evaluated associations of recipient and donor APOE genetic variation with posttransplant outcome.

Precision Medicine for High-Risk Gene Fusions in Pediatric AML: A Focus on KMT2A, NUP98, and GLIS2 Rearrangements

January 15, 2025

[Blood] The authors discuss the current molecular landscape and functional characterization of three of the most lethal childhood AML fusion-oncogene driven subtypes harboring KMT2A, NUP98, or CBFA2T3::GLIS2 rearrangements.

CPSF6-RARγ Interacts with Histone Deacetylase 3 to Promote Myeloid Transformation in RARG-Fusion Acute Myeloid Leukemia

January 14, 2025

[Nature Communications] Using the most prevalent retinoic acid receptor gamma (RARG) fusion, CPSF6-RARG (CR), as a representative, scientists revealed that the CR fusion, enhanced the expansion of myeloid progenitors, impaired their maturation and synergized with RAS mutations to drive more aggressive myeloid malignancies.

Oncogenic Role of RARG Rearrangements in Acute Myeloid Leukemia Resembling Acute Promyelocytic Leukemia

January 14, 2025

[Nature Communications] Scientists showed that RARG fusions disrupted myeloid differentiation and promoted proliferation and self-renewal of hematopoietic stem and progenitor cells by upregulating BCL2 and ATF3.

ONC213: A Novel Strategy to Resensitize Resistant AML Cells to Venetoclax through Induction of Mitochondrial Stress

January 14, 2025

[Journal of Experimental & Clinical Cancer Research] Researchers investigated the antileukemic activity and underlying molecular mechanism of the combination of ONC213 + venetoclax against AML cells. They reported that ONC213 could resensitize venetoclax + azacitidine-resistant AML cells to venetoclax therapy and target leukemia stem cells ex vivo and in vivo.

Gene Therapy for β-Thalassemia: Current and Future Options

January 14, 2025

[Trends in Molecular Medicine] The authors review breakthroughs in gene addition and genome-editing-based therapies for β-thalassemia, the clinical outcomes enabling approval by regulatory agencies, and perspectives for further development.

ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination with Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia

January 14, 2025

[Oryzon Genomics] Oryzon Genomics announced that the first patient has been dosed in a Phase I dose-finding clinical trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with venetoclax and azacitidine in newly diagnosed AML, sponsored by the National Cancer Institute, part of the National Institutes of Health.

CAR T Cell Therapy Breyanzi® (lisocabtagene maraleucel) Approved for Second-Line Relapsed or Refractory Diffuse Large B-cell Lymphoma

January 14, 2025

[Bristol-Myers Squibb Canada] Bristol Myers Squibb Canada announced Health Canada’s approval of Breyanzi®, a type of CAR T therapy, for the treatment of adult patients with diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma.

IRE1α–XBP1 Safeguards Hematopoietic Stem and Progenitor Cells by Restricting Pro-Leukemogenic Gene Programs

January 13, 2025

[Nature Immunology] Investigators uncovered unfolded protein response stress sensor inositol-requiring enzyme-1α (IRE1α) signaling in hematopoietic stem and progenitor cells as a safeguard against myeloid leukemogenesis.

Recipient Sex and Donor Leukemic Cell Characteristics Determine Leukemogenesis in Patient-Derived Models

January 13, 2025

[Haematologica] Scientists reported that, next to leukemic cell characteristics, recipient sex highly influenced the outgrowth of AML cells in patient derived xenografts models, with females being much better repopulated than males in primary as well as secondary transplantation assays.

Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.